Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Victoria J. Muir"'
Publikováno v:
ARKIVOC, Vol 2004, Iss 1, Pp 1-11 (2004)
Externí odkaz:
https://doaj.org/article/0c288b60c72740e0b694615d3fb63b90
Autor:
Victoria J. Muir, Greg L. Plosker
Publikováno v:
CNS Drugs. 34:447-447
During the creation of the HTML version of the article, incorrect body text (including all tables and figures) and an incorrect Additional Information section were uploaded; the PDF version was correct. The HTML version has now been corrected.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a3cf370cb34bc0dc1a35addc4042d71
https://doi.org/10.1007/s40263-020-00712-w
https://doi.org/10.1007/s40263-020-00712-w
Autor:
Sohita Dhillon, Victoria J. Muir
Publikováno v:
BioDrugs. 25:139-146
Erlotinib is a low molecular weight, orally active, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Inhibition of EGFR tyrosine kinase results in the disruption of processes involved in cancer growth and development, including cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49fb2f70f33ac35caaf3be21083506f3
https://doi.org/10.2165/11206910-000000000-00000
https://doi.org/10.2165/11206910-000000000-00000
Autor:
Gillian M. Keating, Victoria J. Muir
Publikováno v:
Drugs. 70:2439-2447
Olmesartan medoxomil is an orally administered angiotensin II receptor antagonist, selective for the angiotensin II type 1 receptor, which has established antihypertensive efficacy in adults. In children and adolescents with hypertension (n = 302), o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55729772e3ee13e1b999d0fa5465162d
https://doi.org/10.2165/11206310-000000000-00000
https://doi.org/10.2165/11206310-000000000-00000
Autor:
Victoria J. Muir, Caroline M. Perry
Publikováno v:
Drugs. 70:1693-1702
Guanfacine, an alpha(2A)-adrenoceptor agonist, is available in the US as an extended-release (ER) tablet for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents (aged 6-17 years). In two large, randomized, dou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::681515f6c4cd70d40941b9889409be6c
https://doi.org/10.2165/11205940-000000000-00000
https://doi.org/10.2165/11205940-000000000-00000
Publikováno v:
Carbohydrate Research. 342:2628-2634
The synthesis of Nalpha-fluorenylmethoxycarbonyl-trans-4-hydroxy-4-O-[(2,3,4,6-tetra-O-acetyl)-alpha-d-mannopyranosyl]-l-proline allyl ester and Nalpha-fluorenylmethoxycarbonyl-trans-4-hydroxy-4-O-[(2,3,4,6-tetra-O-benzoyl)-alpha-d-mannopyranosyl]-l-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a4feb44a2e04d9278587a9596996496
https://doi.org/10.1016/j.carres.2007.08.015
https://doi.org/10.1016/j.carres.2007.08.015
Autor:
David J. Callis, Margaret A. Brimble, Nicholas S. Trotter, Paul W. R. Harris, Victoria J. Muir, Michelle Y. H. Lai
Publikováno v:
Tetrahedron. 61:10018-10035
The synthesis of ten proline-modified analogues of the neuroprotective tripeptide GPE is described. Five of the analogues incorporate a proline residue with a hydrophobic group at C-2 and two further analogues have this side chain locked into a spiro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af61b9a4197cf1f0a86a6b239b05215d
https://doi.org/10.1016/j.tet.2005.08.026
https://doi.org/10.1016/j.tet.2005.08.026
Autor:
Gillian M. Keating, Victoria J. Muir
Publikováno v:
Paediatric drugs. 14(3)
†Adapted and reproduced from the original article published in Drugs 2010; 70 (18): 2439-47.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bb3a08978eddaedbf7cdf58e11ef4fd
https://pubmed.ncbi.nlm.nih.gov/21142262
https://pubmed.ncbi.nlm.nih.gov/21142262
Autor:
Lesley J. Scott, Victoria J. Muir
Publikováno v:
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 25(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91d5e732c600a221a8c9a8fc246a631f
https://pubmed.ncbi.nlm.nih.gov/22050342
https://pubmed.ncbi.nlm.nih.gov/22050342
Autor:
Lesley J. Scott, Victoria J. Muir
Publikováno v:
Drugs. 71(8)
Denosumab, a fully human monoclonal antibody, binds to the receptor activator of nuclear factor-κB ligand (RANKL) and thereby inhibits RANKL-mediated bone resorption. In various individual countries, subcutaneous denosumab is indicated for the preve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eaeb61261d1b27a0daec70f3284b37be
https://pubmed.ncbi.nlm.nih.gov/21668042
https://pubmed.ncbi.nlm.nih.gov/21668042